selected ALT-711 as its lead AGE-breaker based on preclinical results in its annual report for the year 1997 and that it was preparing an IND filing. The INN name was proposed in 2004 and recommended in 2005. In 2006 Alteon merged with a company called HaptoGuard that had cash and a potential diagnostic test for haptoglobin; as part of the merger Genentech, which held preferred shares in Alteon, converted their shares to common ones and received the right to get milestone payments and royalties on sales of alagebrium, and option rights to license ALT-2074. In 2007, the company changed its name to Synvista Therapeutics, Inc. Synvista announced that it was terminating clinical trials of alagebrium in January 2009 in order to focus on the diagnostic test and another clinical candidate SYI-2074 (formerly ALT-2074). The company seems to have discontinued operations and their website is no longer available. See also Glycation Glycosylation Glucosepane Advanced glycation end product References Post-translational modification Thiazoles